share_log

Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease

Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease

Soligenix 與 Silk Road Therapeutics 簽訂獨家期權協議,以獲得旨在治療白塞氏病的局部用己酮可可鹼的權利
Benzinga ·  2023/05/01 07:37

Soligenix Enters into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease

Soligenix 與 Silk Road Therapeutics 簽訂獨家期權協議,以獲得旨在治療 Beh√βset 病的局部用己酮可可鹼的權利

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論